Bli medlem
Bli medlem

Du är här

2016-05-09

Galapagos NV: Galapagos starts Phase 1 study with potentiator GLPG2451 for CF

Galapagos earns $10 million milestone payment from AbbVie

Mechelen, Belgium; 9 May 2016: Galapagos NV (Euronext&NASDAQ: GLPG) announces
the start of a Phase 1 study with potentiator GLPG2451 for cystic fibrosis
(CF). Following GLPG1837, GLPG2451 is the second potentiator compound in
Galapagos' extended CF-portfolio to enter clinical trials.

Galapagos is conducting a randomized, double-blind, placebo-controlled study
over a range of doses of GLPG2451 in healthy volunteers in Belgium and the
Netherlands and expects topline results in Q4 2016. The start of this Phase
1 study triggers a $10 million milestone payment from AbbVie under the
recently expanded global collaboration agreement.

Galapagos and AbbVie aim to develop a triple CFTR combination therapy to
address 90% of patients with CF. In order to bring a more effective therapy
to patients, the companies have developed multiple candidates and backups for
each of the three components of a potential triple combination. GLPG2451 is
the second potentiator and the third compound in the portfolio to enter the
clinic.

Potentiator series

GLPG2451 is the second potentiator candidate to enter clincial evaluation.
Galapagos is recruiting for the SAPHIRA exploratory Phase 2 program with the
first potentiator, GLPG1837, in patients with G551D and S1251N mutations.
Results from the SAPHIRA program are expected in the second half of 2016.

Early binding (C1) corrector series

Dosing to humans of GLPG2222, the first early binding corrector in Galapagos'
portfolio, started in January 2016. Galapagos is conducting a randomized,
double-blind, placebo-controlled study over a range of doses of GLPG2222 in
healthy volunteers in Belgium and expects topline results in Q2 2016.
Earlier this year, Galapagos announced selection of preclinical candidate
GLPG2851, an additional early binding corrector.

Late binding (C2) corrector series

Galapagos announced selection of the first late binding corrector GLPG2665
last year and selection of an additional late binding corrector in the same
series, GLPG2737, this year. Galapagos expects to enter Phase 1 with one of
these late binding correctors in healthy volunteers in the second half of
2016.

More information about the Galapagos-AbbVie collaboration in cystic
fibrosis:www.glpg.com/alliances

More information about cystic fibrosis:www.glpg.com/rd-cystic-fibrosis

About Galapagos

Galapagos (Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our maturing pipeline comprises Phase 2, Phase 1,
pre-clinical and discovery studies in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring this
JAK1-selective inhibitor for inflammatory indications to patients all over
the world. Galapagos is focused on the development and commercialization of
novel medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiaryFidelta, has approximately 400 employees,
operating from its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. More information atwww.glpg.com.

Contacts

------------------------------------------------
| Investors: Media: |
| Elizabeth Goodwin Evelyn Fox |
| VP IR&Corporate Director Communications |
| |
|Communications +31 6 53 591 999 |
|+1 781 460 1784 communications@glpg.com |
| Paul van der Horst |
| |
|Director IR&Business |
|Development |
|+31 6 53 725 199 |
| ir@glpg.com |
------------------------------------------------
Forward-looking statements

This release may contain forward-looking statements, including statements
regarding any anticipated milestone payment, the anticipated timing of
clinical studies, the potential activity of
GLPG1837, GLPG2222, GLPG2451, GLPG2665, GLPG 2737, GLPG2851
and of a potential triple combination including any of these compounds for
cystic fibrosis. Galapagos cautions the reader that forward-looking
statements are not guarantees of future performance. Forward-looking
statements involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition and liquidity,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if Galapagos' results,
performance, financial condition and liquidity, and the development of the
industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future
periods. Among the factors that may result in differences are the inherent
uncertainties associated with competitive developments, clinical trial and
product development activities and regulatory approval requirements
(including that data from Galapagos' ongoing clinical research programs in
cystic fibrosis may not support registration or further development of its
correctors and potentiators due to safety, efficacy or other reasons),
Galapagos' reliance on collaborations with third parties (including the
performance by AbbVie under the Galapagos-AbbVie Collaboration Agreement),
and estimating the commercial potential of its product candidates. A further
list and description of these risks, uncertainties and other risks can be
found in Galapagos' Securities and Exchange Commission (SEC) filing and
reports, including in Galapagos' most recent annual report on Form 20-F filed
with the SEC and subsequent filings and reports filed by Galapagos with the
SEC. Given these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.

GLPG starts Phase 1 study with GLPG2451 for CF
http://hugin.info/133350/R/2010974/744355.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire

HUG#2010974

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.